Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099770 · ClinicalTrials.gov registry record · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
A Phase 3 study of Type 2 Diabetes Mellitus and Chronic Kidney Diseases, sponsored by Prokidney.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 685
- Enrollment target
- 20
- Study locations
NCT05099770 is a Phase 3 study of Type 2 Diabetes Mellitus and Chronic Kidney Diseases that is actively recruiting participants, run by Prokidney. The registered enrollment target is 685 participants, below the 2,743-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05099770, a Phase 3 study of Type 2 Diabetes Mellitus and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Prokidney.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 685 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.
Conditions Studied
Interventions
- PROCEDURE Sham Comparator
- BIOLOGICAL Renal Autologous Cell Therapy (REACT/ rilparencel)
Study Locations (20)
California
- Amicis Research Center - Beverly Hills
- Paradise Clinical Research Group LLC - Glendora
- Kidney Consultants Medical Group - Granada Hills
- IMD Clinical Trials - Huntington Park
- Advanced Medical Research, LLC - Lakewood
- Medicine and Nephrology Associates - Los Alamitos
- Academic Medical Research Institute - Los Angeles
- Southern California Hospital - Los Angeles
- Allameh Medical Corporation - Mission Viejo
- Golden Pacific Nephrology Medical Clinic Inc - Monterey Park
- Northridge Kidney Care Center - Northridge
- Valley Renal Medical Group - Northridge
- Valley Clinical Trials - Northridge
- Integrity Medical Discovery - Pico Rivera
- National Institute of Clinical Research - Pomona
- Nephrology Associates Medical Group - Riverside
- UC Davis Medical Group GI Unit - Sacramento
- North America Research Institute - San Dimas
Alabama
- Nephrology Consultants - Huntsville
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05099770
The ClinicalTrials.gov registry entry for NCT05099770 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,743-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (75% lower). The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT05099770 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05099770 about?
NCT05099770 is a clinical study titled "Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease". The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.
What is the current status of trial NCT05099770?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 685 participants. The study started on 2022-01-05. Estimated completion is 2029-12.
What conditions does trial NCT05099770 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases.
What interventions are being tested in trial NCT05099770?
The interventions under investigation include: Sham Comparator (PROCEDURE), Renal Autologous Cell Therapy (REACT/ rilparencel) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05099770?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05099770 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.